Alluvi, previously BI 4744, represents a significant advance in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://nanobookmarking.com/story22037584/alluvi-a-detailed-examination-into-retatrutide-s-prospects